SCHEMBL5877984

SCHEMBL5877984

CC(CNS(=O)(=O)C(C)C)c1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
GRIA4 P48058 5/20 0.50
MAPT P10636 4/20 0.50
LMNA P02545 2/20 0.50
ALDH1A1 P00352 2/20 0.50
TGFBR1 P36897 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.48
CYP2C19 P33261 1/20 0.48
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NAMPT P43490 1/20 0.47
GPR119 Q8TDV5 4/20 0.47
NPC1 O15118 1/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 1/20 0.45
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11990243 0.82 MAPT (0.58) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL5878625 0.81 MAPT (0.57) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL16504540 0.80 GRIA4 (0.41) MEN1KMT2AGRIA4MAPTALDH1A1
SCHEMBL15243014 0.80 GRIA4 (0.41) MEN1KMT2AGRIA4MAPTALDH1A1
SCHEMBL5877287 0.80 GRIA4 (0.57) GRIA4MAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL5877810 0.79 GRIA4 (0.55) GRIA4ALDH1A1L3MBTL1
SCHEMBL5877827 0.79 GRIA4 (0.57) GRIA4MAPTLMNAALDH1A1NPSR1
SCHEMBL10223333 0.79 MAPT (0.64) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL5573222 0.77 MAPT (0.76) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL21378514 0.77 MAPT (0.61) MEN1KMT2AMAPTLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135487-B2 such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators ELI LILLY AND COMPANY (US) 2006-11-14 US disclosed
US-20060030599-A1 SULPHONAMIDE DERIVATIVES ARNOLD MACKLIN B 2006-02-09 US disclosed
EP-1528055-A2 Sulphonamide Derivatives Eli Lilly & Company (US) 2005-05-04 EP disclosed
EP-0860428-B1 Sulphonamide derivatives LILLY CO ELI (US) 2004-12-08 EP disclosed
US-20040054009-A1 (BIS)sulfonamide derivatives KNOBELSDORF JAMES ALLEN (US) 2004-03-18 US disclosed
US-6596716-B2 2-propane-sulphonamide derivatives ELI LILLY AND COMPANY 2003-07-22 US disclosed
US-6525099-B1 Potentiating glutamate receptor function; psychiatric and neurological disorders ELI LILLY AND COMPANY 2003-02-25 US disclosed
US-20020002158-A1 Sulphonamide derivatives ARNOLD MACKLIN B (US) 2002-01-03 US disclosed
US-6303816-B1 Sulphonamide derivatives ELI LILLY AND COMPANY 2001-10-16 US disclosed
EP-0860428-A2 Sulphonamide derivatives ELI LILLY AND COMPANY (US) 1998-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030599-A1 SULPHONAMIDE DERIVATIVES GRIN2C, GLRA2, GLRA1 MEN1 4556/4885KMT2A 1097/4885GRIA4 19/4885
US-20020002158-A1 Sulphonamide derivatives GRIN2C, GRM1, GRM3 MEN1 4840/4885KMT2A 1738/4885GRIA4 20/4885
US-20040054009-A1 (BIS)sulfonamide derivatives GRIN2A, GRIN2B, GABRE MEN1 4537/4885KMT2A 1739/4885GRIA4 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.